-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2020, esophageal cancer (EC) remained the seventh most common cancer worldwide and the sixth leading cause of cancer-related death
The prognosis of metastatic ESCC is currently poor, with a 5-year survival rate of only 5.
This study, an open-label phase 3 trial, enrolled patients with advanced or metastatic ESCC whose tumors had progressed after first-line systemic therapy and were randomized (1:1) to receive the anti-PD-1 antibody tislelizumab Antibiotics (200 mg/3 weeks) or chemotherapy (investigator's choice paclitaxel, docetaxel, or irinotecan)
All patients in the tislelizumab group had significantly longer overall survival compared to the chemotherapy group All patients in the tislelizumab group had significantly longer overall survival compared to the chemotherapy group
In all patients, tislelizumab treatment was associated with higher objective response rates (20.
Compared with chemotherapy, tislelizumab as a second-line therapy can significantly prolong the overall survival of patients with advanced or metastatic esophageal squamous cell carcinoma with good safety
Original source:
Original Source: Original Source:Lin Shen, et al.
Lin Shen, et al.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Journal of Clinical Oncology.
April 20, 2022.
https://ascopubs.
org/doi/full/10.
1200/JCO.
21.
01926.
Leave a message here